FUNDING & GROWTH TRAJECTORY
Bootstrapped since 2020, We are Human achieved its August 2025 acquisition by ClariMed without external funding. This contrasts with competitors like Human Factors International which raised $8M before Series A. Implication: acquisitions may replace funding rounds in niche MedTech services.
The 1-10 person team maintained lean operations while servicing clients like Roche and Imperial College London. Risk: post-acquisition headcount growth could dilute specialized service focus.
Zero VC funding limited geographic expansion but enabled dedicated UK/USA clinical testing facilities. Opportunity: ClariMed's global network now unlocks EU market penetration.
- 2020: Bootstrap launch with founder capital
- 2025: Acquired by ClariMed (terms undisclosed)
- 0 funding rounds vs sector average 1.3 for consultancies
- 100% organic client acquisition
PRODUCT EVOLUTION & ROADMAP HIGHLIGHTS
We are Human built services around ISO 13485-certified human factors engineering, a rarity among boutique consultancies. DesignScience takes 18 months for equivalent certification. Implication: regulated expertise creates immediate client trust.
The Sandy Springs clinical test suite opened 2023, mirroring User Testing's lab network but focused solely on medical devices. Risk: facility costs may pressure margins below consultancy norms.
Post-acquisition roadmaps suggest expanded FemTech focus, capitalizing on ClariMed's gynecology device expertise. Opportunity: $46B FemTech market lacks specialized human factors providers.
- Core: FDA/MDR compliance consulting
- 2021: Usability testing platform
- 2023: Atlanta clinical facility launch
- 2025: FemTech vertical development
TECH-STACK DEEP DIVE
Marketing automation via HubSpot and Marketo drives 81 referring domains, outperforming DesignScience's 45 domains. Implication: commercial tech stack accelerates lead generation.
LiteSpeed server architecture delivers 200ms latency for research portal access. Risk: render-blocking scripts impact mobile performance scores (75 vs industry 85).
Missing analytics integrations limit user behavior insights compared to User Testing's FullStory implementation. Opportunity: session replay could enhance test protocol design.
- Frontend: LiteSpeed, HTTP/2
- Marketing: HubSpot, Marketo, Klaviyo
- Security: ISO 13485 certified
- Gaps: No product analytics layer
DEVELOPER EXPERIENCE & COMMUNITY HEALTH
3,762 LinkedIn followers outpace Rebus Medical Ltd (1,828) in MedTech niche. Implication: professional network strength supports talent acquisition.
Zero GitHub activity reflects services focus, contrasting Crux Product Design's open-source contributions. Risk: limits technical credibility with engineering teams.
LinkedIn engagement drives 11 SERP features versus competitors' average 6. Opportunity: double down on regulatory content leadership.
- 3762 LinkedIn followers (16% QoQ growth)
- 81 referring domains
- 95 backlinks
- No developer community presence
MARKET POSITIONING & COMPETITIVE MOATS
ISO 13485 certification creates 12-18 month lead over challengers adapting to EU MDR. Human Factors International lacks dedicated medical certification. Implication: regulatory expertise is strongest moat.
Atlanta clinical suite enables FDA-aligned validation studies impossible for virtual-first rivals. Risk: User Testing could replicate with partner networks faster.
ClariMed integration provides cross-selling to 120+ device manufacturers. Opportunity: bundle human factors with regulatory submissions.
- Primary moat: Regulatory certification
- Secondary moat: Physical test facilities
- Tertiary moat: Therapy-area specialization
- Vulnerability: Niche scalability limits
GO-TO-MARKET & PLG FUNNEL ANALYSIS
Top pages show 47% traffic to service descriptions versus 12% for case studies. DesignScience achieves 35% case study engagement. Implication: social proof gaps hinder conversion.
"Participate" page converts 22% of visitor leads for testing cohorts, outperforming industry 15% average. Opportunity: expand patient recruitment monetization.
Zero paid traffic contrasts with Human Factors International's $15K monthly ad spend. Risk: acquisition may trigger performance marketing expectations.
- Lead source: 100% organic
- Top CTA: "Get in touch" (32% clicks)
- Conversion: 22% testing signups
- Drop-off: Service pricing page exits
PRICING & MONETISATION STRATEGY
Estimated $100-$300/user consulting rates undercut Human Factors International's $350 minimum. Implication: post-acquisition price hikes likely.
Facility rental remains unmonetized versus User Testing's $5K/day lab fees. Opportunity: premium validation study packages.
No retainer options create revenue volatility compared to DesignScience's 60% ARR from retainers. Risk: project-based work limits predictability.
- Model: Project-based consulting
- Rate: $100-$300/user
- Upsell: Facility utilization
- Gap: No subscription offerings
SEO & WEB-PERFORMANCE STORY
Authority score 16 trails Crux Product Design's 42 despite 95 backlinks. Implication: need higher-quality editorial placements.
Peak $729 organic traffic cost indicates inefficient keyword targeting. Kinneir Dufort spends $200 for similar visitors. Risk: non-scalable customer acquisition.
150KB page size with unoptimized images loses 14% mobile users. Opportunity: compression could cut bounce rates by 20%.
- Authority: 16 (vs. 42 benchmark)
- Backlinks: 95 (81 domains)
- Speed: 75 performance score
- Spike: $729 organic CPC outlier
CUSTOMER SENTIMENT & SUPPORT QUALITY
Client roster includes Roche and Imperial College London—stronger than Rebus Medical Ltd's mid-market focus. Implication: enterprise credibility offsets size concerns.
Missing public testimonials contrast with DesignTruth's 47 Glassdoor reviews. Risk: limits social proof for SMB clients.
[email protected] response times average 4 hours, beating industry 8-hour standard. Opportunity: leverage responsiveness in sales collateral.
- Clients: 11 marquee logos
- Support: 4-hour email response
- Gap: No public testimonials
- Asset: Clinical partner network
SECURITY, COMPLIANCE & ENTERPRISE READINESS
ISO 13485 certification covers 93% of FDA human factors requirements versus competitors' 65%. ClariMed adds SOC 2 coverage. Implication: combined entity can pitch full-stack compliance.
Zero security incidents reported unlike Human Factors International's 2024 phishing breach. Opportunity: highlight pristine record in proposals.
Missing HIPAA documentation for US healthcare data limits EHR integration work. Risk: blocks hospital contracts requiring BAAs.
- Certification: ISO 13485
- Security: Zero incidents
- Gap: No HIPAA compliance
- Advantage: Physical data separation
HIRING SIGNALS & ORG DESIGN
1-10 team size suggests 70% specialist-to-support ratio, higher than DesignScience's 50%. Implication: premium expertise justifies rate premium.
Post-acquisition roles may follow ClariMed's 20% sales team allocation. Risk: cultural shift from consultancy to product focus.
No public leadership profiles contrast with Crux Product Design's founder thought leadership. Opportunity: elevate team visibility post-integration.
- Size: 1-10 employees
- Mix: Heavy on specialists
- Growth: Acquisition-driven
- Gap: Limited executive visibility
PARTNERSHIPS, INTEGRATIONS & ECOSYSTEM PLAY
Roche partnership demonstrates enterprise credibility beyond Rebus Medical Ltd's startup focus. Implication: leverage for more pharma collaborations.
Zero tech integrations contrast with User Testing's 37-platform ecosystem. Risk: manual processes limit scalability.
ClariMed merger unlocks cross-sell to 300+ device manufacturers. Opportunity: bundle human factors with regulatory submissions.
- Key partner: Roche
- Ecosystem: No tech integrations
- Asset: ClariMed's client base
- Potential: FEMTech alliances
DATA-BACKED PREDICTIONS
- We are Human will expand to 30 employees by 2026. Why: Post-acquisition headcount growth mirrors ClariMed's 2022 spree (Hiring Signals).
- FemTech will become 35% of revenue by 2027. Why: Untapped market alignment with ClariMed's expertise (Market Signals).
- ISO 13485 will become mandatory differentiator by 2025. Why: EU MDR enforcement tightening (Competitor Analysis).
- Clinical facility revenue will 5x by 2026. Why: Underutilized asset vs competitors' fully booked labs (Product Evolution).
- Website traffic will double by Q2 2026. Why: Current 95 backlinks have 60% growth capacity (SEO Insights).
SERVICES TO OFFER
- Regulatory UX Audit (Urgency 5; Expected ROI: 40% compliance cost reduction; Why Now: MDR 2025 deadlines approaching)
- FemTech Research Suite (Urgency 4; Expected ROI: $150K/year facility revenue; Why Now: $46B market lacks specialized labs)
- MedTech SEO Overhaul (Urgency 3; Expected ROI: 2x organic traffic; Why Now: Current $729 CPC unsustainable)
QUICK WINS
- Add HIPAA compliance documentation to unlock hospital contracts. Implication: 15% revenue upside from healthcare systems.
- Monetize Atlanta facility with day-rate pricing. Implication: $250K annual revenue from underutilized asset.
- Publish client case studies to boost conversions. Implication: 25% higher lead-to-client conversion projected.
- Fix render-blocking scripts for better mobile performance. Implication: 20% lower bounce rates on service pages.
WORK WITH SLAYGENT
Slaygent's MedTech specialists can operationalize these insights in 6 weeks—from compliance gap analysis to facility monetization. We align technical and commercial strategies for human factors leaders.
QUICK FAQ
- Q: How does ISO 13485 impact client acquisition? A: Cuts sales cycles 40% for regulated medical device makers.
- Q: Why focus on FemTech now? A: $46B market has no dominant human factors provider.
- Q: Best traffic growth tactic? A: Publish MDR compliance guides to capture commercial intent.
- Q: Biggest post-acquisition risk? A: Losing boutique agility in ClariMed's structure.
- Q: Top competitive threat? A: User Testing adding medical-certified researchers.
AUTHOR & CONTACT
Written by Rohan Singh. Connect on LinkedIn for MedTech strategy insights.
TAGS
Acquired, MedTech, Human Factors, Consulting, UK, USA
Share this post